| Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia JA Powell, AC Lewis, W Zhu, J Toubia, MR Pitman, ... Blood, The Journal of the American Society of Hematology 129 (6), 771-782, 2017 | 88 | 2017 |
| Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies AC Lewis, CT Wallington-Beddoe, JA Powell, SM Pitson Cell Death Discovery 4 (1), 72, 2018 | 81 | 2018 |
| ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism ST Boyle, V Poltavets, J Kular, NT Pyne, JJ Sandow, AC Lewis, ... Nature Cell Biology 22 (7), 882-895, 2020 | 63 | 2020 |
| Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia AC Lewis, VS Pope, MN Tea, M Li, GO Nwosu, TM Nguyen, ... Blood, The Journal of the American Society of Hematology 139 (26), 3737-3751, 2022 | 32 | 2022 |
| Non‐genetic heterogeneity, altered cell fate and differentiation therapy AC Lewis, LM Kats EMBO molecular medicine 13 (3), e12670, 2021 | 30 | 2021 |
| Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma J Wong, E Gruber, B Maher, M Waltham, Z Sabouri-Thompson, I Jong, ... Leukemia 36 (6), 1654-1665, 2022 | 16 | 2022 |
| Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia J So, AC Lewis, LK Smith, K Stanley, R Franich, D Yoannidis, L Pijpers, ... EMBO Molecular Medicine 14 (7), e15203, 2022 | 15 | 2022 |
| Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1 JA Powell, MR Pitman, JR Zebol, PAB Moretti, HA Neubauer, LT Davies, ... Biochemical Journal 476 (21), 3211-3226, 2019 | 15 | 2019 |
| Identification of sphingosine kinase 1 as a therapeutic target in B‐lineage acute lymphoblastic leukaemia. CT Wallington‐Beddoe, V Xie, D Tong, JA Powell, AC Lewis, L Davies, ... British journal of haematology 184 (3), 2019 | 15 | 2019 |
| The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism MR Pitman, AC Lewis, LT Davies, PAB Moretti, D Anderson, DJ Creek, ... Scientific Reports 12 (1), 454, 2022 | 14 | 2022 |
| Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells E Gruber, J So, AC Lewis, R Franich, R Cole, LG Martelotto, AJ Rogers, ... Cell Reports 40 (7), 2022 | 10 | 2022 |
| Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models E Morrish, A Copeland, DM Moujalled, JA Powell, N Silke, A Lin, ... Blood Advances 4 (20), 5062-5077, 2020 | 10 | 2020 |
| The MCL-1 inhibitor S63845: an exciting new addition to the armoury of anti-cancer agents JA Powell, AC Lewis, SM Pitson Journal of Xiangya Medicine 2 (6), 2017 | 6 | 2017 |
| Publisher Correction: ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism. ST Boyle, V Poltavets, J Kular, NT Pyne, JJ Sandow, AC Lewis, ... Nature Cell Biology 22 (7), 908-909, 2020 | 5 | 2020 |
| ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism (vol 71, pg 861, 2020) ST Boyle, V Poltavets, J Kular, NT Pyne, JJ Sandow, AC Lewis, ... NATURE CELL BIOLOGY 22 (7), 908-908, 2020 | 1 | 2020 |
| The emerging role of sphingolipids in cancer stem cell biology AC Lewis, JA Powell, SM Pitson Lipidomics of Stem Cells, 151-170, 2017 | 1 | 2017 |
| 3099–HEME BIOSYNTHESIS IS A THERAPEUTIC VULNERABILITY IN ACUTE MYELOID LEUKAEMIA L Kats, A Lewis, E Gruber, R Franich, K Brown, R Johnstone Experimental Hematology 137, 104421, 2024 | | 2024 |
| Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukaemia. AC Lewis, E Gruber, R Franich, J Armstrong, MJ Kelly, CM Opazo, ... bioRxiv, 2024.08. 11.607520, 2024 | | 2024 |
| Quantitating and Characterizing the Effects of Epigenetic Targeted Drugs E Gruber, AC Lewis, LM Kats Precision Cancer Therapies, Volume 1‐Targeting Oncogenic Drivers and …, 2023 | | 2023 |
| 3113–IDENTIFICATION OF HEME AS A CRITICAL REGULATOR OF LEUKEMOGENESIS A Lewis, E Gruber, M Kelly, R Franich, K Ting, K Brown, L Kats Experimental Hematology 124, S106, 2023 | | 2023 |
